Asymmetric dimethylarginine as a potential biomarker for management and follow-up of phenylketonuria

• Published in: European journal of pediatrics Vol. 178; no. 6; pp. 903 - 911
• Main Authors: Andrade, Fernando, Villate, Olatz, Couce, María L., Bueno, María A., Alcalde, Carlos, de las Heras, Javier, Ceberio, Leticia, Núñez-Marcos, Sergio, Nambo, Pablo Suárez, Aldámiz-Echevarría, Luis
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-06-2019; Springer Nature B.V
• Subjects: Arginine; Arginine - analogs & derivatives; Arginine - blood; Biomarkers; Biomarkers - blood; Case-Control Studies; Child; Creatinine; Creatinine - blood; Cross-Sectional Studies; Diet; Diet, Protein-Restricted - adverse effects; Female; Homocysteine; Humans; Low protein diet; Male; Management; Medicine; Medicine & Public Health; Metabolic pathways; Metabolism; Nutrient deficiency; Original Article; Patients; Pediatrics; Phenylalanine; Phenylketonuria; Phenylketonurias - blood; Phenylketonurias - diet therapy; Spain; Statistical analysis; Spain; Asymmetric dimethylarginine; Biomarker; Phenylketonuria
• ISSN: 0340-6199; 1432-1076
• DOI: 10.1007/s00431-019-03365-0

Phenylketonuria’s (PKU) treatment based on low-protein diet may affect other metabolic pathways, such as that of asymmetric dimethylarginine (ADMA). The aim of this study was to evaluate the reliability of ADMA as a biomarker of adequate metabolic control and possible nutritional risk in a long-term PKU patient population. One hundred and six dietary-treated PKU patients from four hospitals in Spain were enrolled in this cross-sectional study. Their lipid profile, total homocysteine, ADMA, and symmetric dimethylarginine (SDMA) concentrations were analyzed and compared with a control group. Sensitivity, specificity, and likelihood ratios of the proposed biomarker were calculated. PKU patients had statistically significant lower plasmatic ADMA, SDMA, and arginine concentrations as compared with the control group (
p
 < 0.001). Significant correlations were found between ADMA, phenylalanine, and total homocysteine levels. The ADMA/creatinine ratio correlated with phenylalanine levels as metabolic control and nutritional risk in PKU patients. Its reliability as a management biomarker was studied with positive results. The ADMA/creatinine ratio might serve as an independent biomarker in the management of PKU patients, different from blood phenylalanine levels. It could be of particular usefulness to detect those who are following an unbalanced diet that could have long-term negative effects.
Conclusion
: In this study, we have evaluated the reliability of ADMA as a potential biomarker of adequate metabolic control and possible nutritional risk in a long-term PKU patient population.
What is Known:
•
Although PKU individuals have lower values of ADMA even with blood Phe levels in the recommended range, little attention is payed to other metabolic pathways.
What is New:
•
ADMA could be used as new biomarker for PKU management and follow-up of the diet, after evaluating their reliability in a long-term PKU patient population
.